梅州怀孕三个多月能做人流吗(梅州脂肪填充 泪沟) (今日更新中)

HONG KONG, July 19 (Xinhua) -- A gene controlled by male hormone was critical for the growth of liver tumor, leading to a higher incidence of the disease in men than in women, according to the Chinese University of Hong Kong which made the results public on Tuesday.There is a significant gender bias in liver cancer incidence. In Hong Kong, men are three times more likely to develop liver cancer than women. Such phenomenon prompted researchers from the university to carry out a genomic location analysis in liver cancer cells starting from 2008.The researchers discovered, out of 17,000 human genes, that a gene called Cell Cycle-Related Kinase (CCRK) was directly controlled by androgen receptor. They further found that CCRK was critical for the induction of signaling pathway leading to abnormal liver cell growth and tumor formation.The results also reveal that 70 percent of patients with liver cancer were found to produce high levels of CCRK. More importantly, these patients were more likely to have late-stage cancers and lived shorter than those with low CCRK level.Using mouse models, the researchers found that either lowering the level or blocking the signaling pathway of CCRK in liver cancer cells could significantly reduce the tumor growth rate.The study has validated that CCRK is an important gene that has potential to cause liver cancer and the gene can be tested as a new targeted therapy in future.Vice-Chancellor of the university Joseph Sung, who is also team leader of the research project, said the results explained why men have a higher risk of liver cancer than women and helped push ahead with the development of a novel treatment of the disease.The above study results were published online in July in Journal of Clinical Investigation.

SAN FRANCISCO, Sept. 13 (Xinhua) -- Intel and Google on Tuesday announced a partnership to enable the world's largest chip maker's architecture on the search giant's products, saying that an Intel chip-based Android smartphone will hit the market in the first half of 2012.In a joint press release, the two companies said the future versions of Android mobile operating system will support Intel's low power Atom processors, in addition to other architectures.At the Intel Developer Forum in San Francisco on Tuesday, Intel Chief Executive Officer Paul Otellini said the Intel smartphone chip is code-named Medfield and based on the company's own PC- based computer architecture.Otellini said multiple vendors around the world will launch the Medfield-based Android smartphones in the first half of 2012.Andy Rubin, senior vice president of mobile at Google, came on stage at the close of Otellini's keynote to hail the joint initiatives between the two companies.Intel has been struggling to get a bite of the booming market of smartphones and tablets. Most of the current mobile devices use chips based on architecture from ARM Holdings, which are considered more power efficient than Intel's products. Nokia had planned to ship smartphones with Intel chips this year, but it shifted to ARM-based phones with Windows Phone 7 system.Otellini said Intel will eventually have an advantage in supplying smartphone chips as the business is not established in terms of the final winner and performance of the products keeps growing.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

LOS ANGELES, June 7 (Xinhua) -- Salmonella, not E. coli, poses the greatest health threat to Americans, the U.S. Centers for Disease Control and Prevention (CDC) announced on Tuesday.Salmonella infections have risen 10 percent over the past 15 years, while several types of foodborne illness have been falling, the agency said in a report.Infections from Shiga toxin-producing E. coli O157 (the strain of most concern in the United States) have dropped almost in half and the rates of six other foodborne infections have been cut 23 percent, the CDC said.The agency issued the report as a deadly new strain of E.coli is spreading in several European countries."There are about 50 million people each year who become sick from food in the U.S.. That's about one in six Americans," CDC director Dr. Thomas R. Frieden said.The CDC attributed the reduction in infections from E. coli O157 to better detection and investigation of outbreaks, cleaner slaughterhouse methods, better testing of ground beef for E. coli, improved inspections of ground beef processing plants, regulations prohibiting E. coli O157 in ground beef and increased awareness of the importance of properly cooking beef.Other foodborne illnesses that fell in incidence over the same time period include those caused by the campylobacter, listeria, vibrio and yersinia pathogens.To reduce their risk of foodborne illness, people should assume that raw chicken and other meat have bacteria that can make you sick, the CDC said.In the kitchen, raw meats should not allow to contaminate counter tops or cutting boards and should be kept away from other foods, such as fruits and vegetables, the CDC advised.The agency also called on people to thoroughly cook meat, poultry, eggs and shellfish, while refraining from consuming unpasteurized milk, juice or soft cheese.

SHENYANG, Aug. 16 (Xinhua) -- Two more cutaneous anthrax infections were reported in northeast Liaoning Province, bringing the total number of people who were hospitalized for the disease to 32, health authorities said Tuesday.The two cases were found Monday in Donggang City, more than 100 km away from the city where the disease was first reported, the Liaoning Provincial Health Department said in a statement.Health experts noted that all the cases originated from the the same source.As of 8 p.m. Monday, four cases have been confirmed while 28 others were still being investigated, according to the health department.An initial investigation by local health authorities showed that the patients contracted the disease after direct contact with diseased cattle.The government of Liaoning has since killed or disinfected more than 400 heads of cattle in the province and carried out a survey among over 20,000 people.Cutaneous anthrax is an infection of the skin caused by direct contact with infected animals or animal products. It is rarely fatal if treated.

来源：资阳报